← Back to Clinical Trials
Recruiting NCT06468319

NCT06468319 Pregnancy Registry in Mali

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06468319
Status Recruiting
Phase
Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Condition Malaria
Study Type OBSERVATIONAL
Enrollment 9,500 participants
Start Date 2024-08-05
Primary Completion 2030-06

Eligibility & Interventions

Sex Female only
Min Age 15 Years
Max Age 49 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 9,500 participants in total. It began in 2024-08-05 with a primary completion date of 2030-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This registry will assess pregnancy outcomes through demographic surveillance and prospective data collection at a health facility in Kalifabougou, Mali.

Eligibility Criteria

Inclusion Criteria: Community Census Cohort: 1. Females of childbearing potential or pregnant females. 2. Aged 15 to 49 years. 3. Able to provide verbal individual informed consent. Health Facility Cohort: 1. Pregnant females 15 to 49 years and their subsequent offspring. 2. Resides in or in the health catchment area of Kalifabougou and willing to return to the health center for Antenatal Care (ANC) visits. 3. Able to provide written individual informed consent for herself and her future offspring(s). Exclusion Criteria: Community Census Cohort: 1. Temporary residence in the study area. 2. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of an individual participating in the study, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol. Health Facility Cohort: 1. Temporary residence in the study area. 2. Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of an individual participating in the study, interfere with the evaluation of the study objectives, or render the participant unable to comply with the protocol.

Contact & Investigator

Central Contact

Kassoum Kayentao, MD, MPH, PhD

✉ kayentao@icermali.org

📞 +223 7646 0173

Principal Investigator

Kassoum Kayentao, MD, MPH, PhD

PRINCIPAL INVESTIGATOR

Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS)

Frequently Asked Questions

Who can join the NCT06468319 clinical trial?

This trial is open to female participants only, aged 15 Years or older, up to 49 Years, studying Malaria. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06468319 currently recruiting?

Yes, NCT06468319 is actively recruiting participants. Contact the research team at kayentao@icermali.org for enrollment information.

Where is the NCT06468319 trial being conducted?

This trial is being conducted at Kalifabougou, Mali.

Who is sponsoring the NCT06468319 clinical trial?

NCT06468319 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Kassoum Kayentao, MD, MPH, PhD at Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS). The trial plans to enroll 9,500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology